Chemotherapy: Open Access
Open Access
ISSN: 2167-7700
ISSN: 2167-7700
Department of Medical Oncology, Kartal Dr. Lütfi Kirdar Hospital, Health Science University, Turkey
Research Article
Association of New Inflammatory Markers Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte (MCVL) with Anti PD-1 Antibody Nivolumab Treatment Response in Metastatic Renal Cell Carcinoma
Author(s): Heves Surmeli*, Deniz Isik, Hamit Bal, Salih Tunbekici, Oguzcan Kinikoglu, Yunus Emre Altintas, Goncagul Akdag and Sedat Yildirim
Introduction: Kidney cancer is an immunogenic tumor and inflammation plays a role in tumor formation and progression. The aim of this study was to investigate the effect of biochemical markers in predicting treatment response in patients with metastatic Renal Cell Carcinoma (RCC) receiving nivolumab treatment.
Methods: Patients aged ≥ 18 years who received nivolumab treatment for metastatic RCC between February, 2022 and January, 2024 were evaluated. Cellular blood count was evaluated at the diagnosis of metastatic disease and periodically during nivolumab treatment. We measured the cell count in peripheral blood at admission and calculated the inflammation indices obtained from the blood cell count as follows: MCVL (Mean Corpuscular Volume/Lymphocytes) and IIC ((mean corpuscular volume *width of erythrocyte distribution* neutrophils/(lym.. View More»
DOI:
10.35248/2167-7700.24.12.227